BP-010

BP-010 is a pediatric oral reformulation of a carbonic anhydrase inhibitor developed by Brillian Pharma. Utilizing the company's proprietary "Unidose" delivery technology, the drug is designed as an oral solution or a lyophilized powder for reconstitution, aimed at providing precise single-dose administration suitable for children. Carbonic anhydrase inhibitors are a class of pharmaceuticals that suppress the activity of carbonic anhydrase enzymes, which are involved in regulating fluid secretion and acid-base balance in various tissues. Common therapeutic applications for this class include the treatment of glaucoma, idiopathic intracranial hypertension, altitude sickness, and certain forms of epilepsy. The specific active pharmaceutical ingredient and primary target indication for BP-010 have not been publicly disclosed by Brillian Pharma.